September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
164 citations
,
January 2003 in “Drugs”
63 citations
,
May 2011 in “Clinical cancer research” The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
19 citations
,
March 2010 in “Steroids” Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.
2 citations
,
January 2025 in “Journal of Clinical Immunology” 10 citations
,
July 1994 in “Journal of Dermatological Science” Cyclosporin extends hair growth in mice, but high-dose corticosteroids block this effect.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib significantly improves hair regrowth in severe alopecia areata.
September 2024 in “Polish Journal of Public Health” Prescription tablets treat hirsutism, while over-the-counter foams treat hypertrichosis.
37 citations
,
May 1997 in “The Journal of Clinical Endocrinology & Metabolism” MK-386 lowers DHT in blood and skin but not in semen.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
3 citations
,
February 2010 in “Clinical kidney journal” Combining ciclosporin and simvastatin can cause severe kidney damage.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
26 citations
,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
59 citations
,
February 2021 in “BMJ” High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
October 2020 in “Journal of the American Society of Nephrology” Drospirenone can hide symptoms of certain hormonal disorders, complicating diagnosis.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
January 2021 in “Journal of Shaheed Suhrawardy Medical College” Cyproterone acetate and ethinylestradiol significantly lowered AMH levels in PCOS patients resistant to clomiphene.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
Baricitinib shows promise for treating alopecia areata with mild side effects.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
11 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.
42 citations
,
September 2018 in “Journal of Fungi” Terbinafine and itraconazole are more effective against Microsporum canis than fluconazole and griseofulvin.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
90 citations
,
May 2019 in “Drugs” Long-term use of azole antifungals can cause hair loss, hormonal imbalances, and severe skin reactions.
21 citations
,
August 1984 in “BJOG An International Journal of Obstetrics & Gynaecology” Ovarian function was similar in both treatment groups, but both caused excessive hair growth.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.